Vor Biopharma (NASDAQ:VOR) Stock Price Up 6.2% - Time to Buy?

Key Points

• Vor Biopharma shares rose 6.2% to $24.04, although trading volume was about 92% below the average session volume.
• Analysts maintain a broadly positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $43.38; however, the company missed its latest quarterly EPS estimate, reporting a loss of $0.80 versus expectations of $0.69.
• Institutional investors own a substantial 97.29% of the stock, while the clinical-stage biotechnology company advances VOR33, an engineered stem-cell therapy candidate for relapsed or refractory AML and high-risk MDS.

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) was up 6.2% on Wednesday . The company traded as high as $24.01 and last traded at $24.04. Approximately 79,561 shares traded hands during mid-day trading, a decline of 92% from the average session volume of 1,036,914 shares. The stock had previously closed at $22.64.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the stock. Weiss Ratings upgraded shares of Vor Biopharma from a "sell (d-)" rating to a "sell (d+)" rating in a report on Tuesday, August 11th. Wall Street Zen upgraded shares of Vor Biopharma from a "sell" rating to a "hold" rating in a research report on Saturday, August 15th. HC Wainwright restated a "buy" rating and set a $31.00 price objective on shares of Vor Biopharma in a research report on Monday, May 18th. Finally, Wedbush raised their price target on shares of Vor Biopharma from $18.00 to $27.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 12th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Vor Biopharma currently has a consensus rating of "Moderate Buy" and an average target price of $43.38.

Vor Biopharma Stock Performance

The company's 50 day moving average price is $20.71 and its 200 day moving average price is $16.85.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.11). On average, analysts anticipate that Vor Biopharma Inc. will post -2.56 EPS for the current fiscal year.

Institutional Investors Weigh In On Vor Biopharma

A number of institutional investors and hedge funds have recently made changes to their positions in the company. RA Capital Management L.P. boosted its holdings in Vor Biopharma by 172.7% in the fourth quarter. RA Capital Management L.P. now owns 5,404,998 shares of the company's stock valued at $70,697,000 after acquiring an additional 3,422,697 shares during the last quarter. Fcpm Iii Services B.V. raised its holdings in Vor Biopharma by 852.8% during the 4th quarter. Fcpm Iii Services B.V. now owns 3,617,354 shares of the company's stock worth $47,315,000 after purchasing an additional 3,237,714 shares during the last quarter. Frazier Life Sciences Management L.P. bought a new stake in Vor Biopharma during the 4th quarter worth about $33,275,000. Paradigm Biocapital Advisors LP acquired a new position in Vor Biopharma during the 4th quarter valued at about $22,890,000. Finally, NEXTBio Capital Management LP acquired a new position in Vor Biopharma during the 4th quarter valued at about $13,080,000. Institutional investors own 97.29% of the company's stock.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company's proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient's immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source